Janssen publishes positive safety and efficacy data for single-dose COVID-19 vaccine
Janssen publishes phase 3 trial data from study showing positive
safety and efficacy results for its single-dose COVID-19 vaccine
Vaccine shown to be 66% effective overall in preventing coronavirus
in participants UK has secured 30 million doses with deliveries
expected to arrive this year if approved by regulators Janssen
today (29 January) published positive data from...Request free trial
Janssen today (29 January) published positive data from the phase 3 studies of its single-dose Covid-19 vaccine candidate, showing it to be 66% effective overall in preventing coronavirus in participants. The data did not report any significant safety concerns relating to the vaccine, with no serious adverse events in vaccine recipients. The UK has secured 30 million doses of Janssen’s vaccine last summer, with deliveries expected to arrive in the second half of this year if approved for use by the Medicines and Healthcare products Regulatory Agency (MHRA), who will review and analyse the relevant data to see if the vaccine meets their strict standards of safety and effectiveness. Today’s results are for Janssen’s single-dose study. Phase 3 trials for the company’s two-dose regimen are ongoing worldwide, including in the UK at 16 National Institute for Health Research (NIHR) sites across the country. These trials involve more than 6,000 volunteers in the UK, some of whom were recruited from the NHS Vaccines Registry. While a single dose of a safe and effective vaccine would offer a significant advantage during a global pandemic emergency, a two-dose schedule may have the potential to offer enhanced durability in some participants. Data from this multi-country study is expected later this year. Business Secretary Kwasi Kwarteng said:
The Janssen vaccine works in the same way as vaccine developed by Oxford and AstraZeneca and is designed to prompt an immune response including neutralising antibodies against the spike protein to eliminate the virus. Again similarly to the Oxford/AstraZeneca vaccine it can be safely stored and transported at standard refrigeration temperatures. Health Secretary Matt Hancock said
Vaccines Minister Nadhim Zahawi said:
Through the Vaccines Taskforce, the UK has secured early access to 367 million doses of seven of the most promising vaccines so far. To date, the UK government has invested over £230 million into manufacturing a successful vaccine. The UK was the first country in the world to procure, authorise and then deploy both the Oxford/AstraZeneca and Pfizer/BioNTech vaccines. Production of the Oxford University/AstraZeneca vaccine started last autumn where the bulk of the vaccine for the UK is being made in Oxfordshire and Staffordshire, with filling into vials taking place in North Wales. In total, more than 7.4 million people across the UK have now had a least one dose of the vaccine. Notes to editors
|